Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection.
A sensitive high-performance liquid chromatographic (HPLC) method for the quantitation of the HMG-CoA reductase inhibitor pravastatin in human plasma is described. Sample preparation based on reversed-phase solid-phase extraction using triamcinolone acetonide as internal standard (I.S.). The compounds were separated on C18 reversed-phase analytical column and then determined by ultraviolet detection. The recovery of pravastatin from plasma was 69.2+/-6.7% (mean+/-S.D.). The limit of detection for pravastatin in aqueous solution was 0.4 ng, the limit of quantitation in plasma was 2 ng/ml. In a preliminary pharmacokinetic study with two healthy volunteers the t1/2 of pravastatin in plasma was found to be 0.8 and 2.3 h.
Otter
K
K
Department of Pharmacology, Christian-Albrechts University, Kiel, Germany.
Mignat
C
C
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000097:blood* / Q000493:pharmacokinetics; D017035:Pravastatin / Q000097:blood*; D012680:Sensitivity and Specificity
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin